Equity research analysts and clinical-stage biotechnology brokerages tracking NervGen Pharma Corp. (NASDAQ: NGEN) maintain optimistic consensus price targets that project substantial valuation upside, heavily contingent upon the successful clinical advancement and future trial data readouts of its lead neuroreparative drug candidate, NVG-291. Because clinical-stage biotech valuations fluctuate based on regulatory milestones, trial progress, and funding announcements, long-term projections reflect a high-risk, high-reward risk profile.